StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Viridian Therapeutics, Inc.\DE's ebitda for the twelve months ending Jun 30, 2026 was -$404.73M. For fiscal 2025 it was -$362.94M. The highest annual figure on record is -$49.00K in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$362.94M–
FY2024Dec 31, 2024-$298.50M–
FY2023Dec 31, 2023-$253.93M–
FY2022Dec 31, 2022-$134.05M–
FY2021Dec 31, 2021-$79.61M–
FY2020Dec 31, 2020-$110.14M–
FY2019Dec 31, 2019-$41.69M–
FY2018Dec 31, 2018-$32.80M–
FY2017Dec 31, 2017-$26.22M–
FY2016Dec 31, 2016-$16.65M–
FY2015Dec 31, 2015-$11.00M–
FY2014Dec 31, 2014-$6.72M–
FY2013Dec 31, 2013-$49.00K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$126.15M–
Q1 FY2026Mar 31, 2026-$116.05M–
Q4 FY2025Dec 31, 2025-$122.63M–
Q3 FY2025Sep 30, 2025-$39.90M–
Q2 FY2025Jun 30, 2025-$106.65M–
Q1 FY2025Mar 31, 2025-$93.75M–
Q4 FY2024Dec 31, 2024-$87.35M–
Q3 FY2024Sep 30, 2024-$83.35M–
Q2 FY2024Jun 30, 2024-$72.05M–
Q1 FY2024Mar 31, 2024-$55.75M–
Q4 FY2023Dec 31, 2023-$71.33M–
Q3 FY2023Sep 30, 2023-$51.09M–
Q2 FY2023Jun 30, 2023-$59.14M–
Q1 FY2023Mar 31, 2023-$72.37M–
Q4 FY2022Dec 31, 2022-$48.97M–
Q3 FY2022Sep 30, 2022-$29.72M–
Q2 FY2022Jun 30, 2022-$29.51M–
Q1 FY2022Mar 31, 2022-$25.85M–
Q4 FY2021Dec 31, 2021-$29.05M–
Q3 FY2021Sep 30, 2021-$14.10M–
Q2 FY2021Jun 30, 2021-$17.97M–
Q1 FY2021Mar 31, 2021-$18.48M–
Q4 FY2020Dec 31, 2020-$90.55M–
Q3 FY2020Sep 30, 2020-$5.35M–
Q2 FY2020Jun 30, 2020-$6.31M–
Q1 FY2020Mar 31, 2020-$7.93M–
Q4 FY2019Dec 31, 2019-$10.00M–
Q3 FY2019Sep 30, 2019-$11.13M–
Q2 FY2019Jun 30, 2019-$8.84M–
Q1 FY2019Mar 31, 2019-$11.66M–
Q4 FY2018Dec 31, 2018-$10.38M–
Q3 FY2018Sep 30, 2018-$9.05M–
Q2 FY2018Jun 30, 2018-$8.76M–
Q1 FY2018Mar 31, 2018-$4.55M–
Q4 FY2017Dec 31, 2017-$6.27M–
Q3 FY2017Sep 30, 2017-$5.79M–
Q2 FY2017Jun 30, 2017-$7.25M–
Q1 FY2017Mar 31, 2017-$6.87M–
Q4 FY2016Dec 31, 2016-$5.83M–
Q3 FY2016Sep 30, 2016-$3.98M–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?